Sort
21,453 grants matching “tuberculosis”
B12 Trafficking and Inherited Defects
$583,386Ruma V Banerjee · University Of Michigan At Ann Arbor · R01 · FY2023 · DK
Immune correlates of LTBI in HIV-exposed infants
$583,360Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2022 · AI
Interplay of Transition Metal Homeostasis and Reactive Sulfur Species in Bacterial Pathogens
$583,052David P. Giedroc · Trustees Of Indiana University · R35 · FY2020 · GM
Elucidating the path to type I IFNs in TB infection
$582,940Amy K Barczak · Massachusetts General Hospital · R01 · FY2021 · AI
Modeling Core
$582,660Nitin S Baliga · Seattle Biomedical Research Institute · U19 · FY2017 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$582,558Mary Goggin · Colorado State Dept/Pub Hlth & Environmt · U52 · FY2010 · PS
Hybrid trial for Alcohol reduction among people with TB and HIV in India (HATHI)
$582,471Amita Gupta · Johns Hopkins University · R01 · FY2022 · AA
Molecular pathogenesis of Blastomycosis
$582,368Bruce Steven Klein · University Of Wisconsin-Madison · R01 · FY2017 · AI
Testing the Combination of Behavioral Activation and Problem Solving as a Novel Behavioral Smoking Cessation Intervention for Smokers with HIV in Botswana
$582,347Robert Gross · University Of Pennsylvania · R01 · FY2024 · DA
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa
$582,230Max O'Donnell · Columbia University Health Sciences · R01 · FY2016 · AI
A Cambodian Clinical Research Network for HIV &TB
$582,201Cambodian Health Committee · U01 · FY2005 · AI
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis
$582,022Shabaana A. Khader · University Of Chicago · R01 · FY2025 · HL
Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis
$582,022Shabaana A. Khader · University Of Chicago · R01 · FY2023 · HL
Optimizing vaccine science to improve the outcome of tuberculosis treatment
$581,924Selvakumar Subbian · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI
Clinical Core
$581,522Richard Douglas Moore · Johns Hopkins University · P30 · FY2020 · AI
Multi-level and Intersectional Stigma and other Social Determinant Effects on TB Case Detection, Care, and Treatment Outcomes: The MISSED TB Outcomes Study
$581,520Andrew Medina-Marino · Desmond Tutu Hiv Foundation · R01 · FY2021 · AI
Effectiveness of the TB Contact Priority Model
$581,422Lynn B Gerald · University Of Alabama At Birmingham · R01 · FY2006 · HL
Infectious Disease/Basic Microbial Pathogenic Mechanisms
$581,385Daniel E Goldberg · Washington University · T32 · FY2024 · AI
Development Of New Chemotherapeutics For Tuberculosis
$581,288Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Exploring the metabolism of non-replicating and drug-resistant TB
$581,288Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$581,288Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
The Impact of Diabetes on TB treatment outcomes
$581,164Jonathan E Golub · Johns Hopkins University · R01 · FY2015 · AI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India
$580,907Shruti H Mehta · Johns Hopkins University · R01 · FY2012 · DA
Testing Novel Interventions to Protect Workers from Airborne Infections
$580,894Edward A. Nardell · Brigham And Women'S Hospital · R01 · FY2012 · OH
Mapping eQTLs that affect susceptibility to Tuberculosis
$580,479Yoav Gilad · University Of Chicago · R01 · FY2011 · AI